home > news > detailed info

Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern Europe

Myeloma Patients Europe

Brussels, 30 November 2022 – Myeloma Patients Europe (MPE) has launched a first-of-its-kind advocacy report on  Addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE).

The report, led by the MPE CEE Workgroup on Access, found huge inequalities for patients, confirming reports from MPE CEE members about a lack of clinical trials opening in the region and difficulties in patient participation.

Biba Dodeva, MPE Board Member and Chair of the MPE CEE Workgroup on Access commented:
“This is an important report which for the first time shines a light on the differences in myeloma trial access between countries and explores potential reasons for this. In my country, North Macedonia, we do not have access to many clinical trials, and this is a situation replicated across the Balkans. I very much hope this report and recommendations lead to discussion, best practice sharing and identified action on improving the situation for patients across CEE.”

The MPE report presents clinical trial analytics, looking at the number of clinical trials held in CEE countries between 1 January 2001 and 28 September 2020. The analytics found:
  • Only 6% of the 3,229 worldwide myeloma trials included patients from CEE countries
  • Of the 17 CEE countries that ran at least one myeloma clinical trial, 11 were EU members
  • Czech Republic (128 trials), Poland (95 trials) and the Russian Federation (79 trials) were involved in the largest number of trials
  • In relative terms to myeloma prevalence, Czech Republic, Hungary (66 trials) and Bulgaria (24 trials) were the CEE countries most efficient in conducting research
  • Seven countries had no access to myeloma clinical trials and 12 countries had fewer than five myeloma clinical trials

To explore the analytics further, MPE conducted a literature review exploring the barriers and facilitators to clinical trial access in Europe, alongside qualitative interviews with haematologists, researchers and regulators in three selected CEE countries (Poland, Croatia and Macedonia). Key findings include:
  • Population size (and subsequent patient population) is an important, but not the only, determinant in where clinical trials launch
  • Trial access in CEE countries is strongly correlated to EU membership
  • Most myeloma clinical trials in CEE are run by the pharmaceutical industry (around 80%) given their ability to invest in and finance such research
  • Lack of reimbursement and access to “standard of care” treatment in myeloma (e.g. ESMO-EHA myeloma guidelines) make it difficult for trials to run in some countries. For example, impacting on the trial eligibility of patients and the comparator arm of trials
  • For “innovative” immunotherapies and cancer drugs, such as CAR-T and bispecifics, additional resources, monitoring and diagnostics tools need to be in place to run trials, which some countries do not have
  • A lack of adequate staffing and workforce planning was identified as a barrier to trial set-up in countries. The situation has worsened with the increasing number of physicians and nurses leaving some CEE countries to work in Western Europe (the “brain drain”)
  • Too much bureaucracy and administration for setting up trials (e.g. registration, ethics) impacts on access. This has the biggest impact on access to academic trials which are less well resourced
  • Even where trials are available within CEE countries, patients face access barriers related to factors including geography and socio-economic aspects

The report subsequently makes a series of 27 recommendations for key stakeholders (including researchers, industry, policymakers and advocates) designed to promote discussion on potential solutions for improving clinical trial access across CEE. The recommendations relate to the following topics: promoting regional and international collaboration on clinical trials and research; facilitating international peer-to-peer support and knowledge sharing on clinical trials; minimum staffing requirements or guidelines; creating a supportive policy environment for research and R&D; improved information and communication on clinical trials for patients; and, improving the wider access environment including medicines access and diagnostics.

For the full list of findings and recommendations, you can see the Executive Summary and Full Report here.

Next steps
The report has been launched today during an MPE online event. During the event, the report and recommendations were presented, alongside case studies from North Macedonia, Czech Republic and Poland. The event recording will be available soon on our website.

You can see a pre-recorded video from speaker Prof Oliver Karanfilski on the challenges running clinical trials in North Macedonia here.

In 2023, MPE plans to hold a multi-stakeholder, roundtable discussion on the issues and recommendations included in the report to further analyse the access barriers and facilitators to clinical trials in CEE. If you are interested in this work, please email

Finally, this work was developed and steered by the MPE CEE workgroup on access. Again, if you are interested in joining this workgroup, please email
email Avenue Louise 143/4, 1050 Brussels Belgium
Print this page
Send to a friend
News and Press Releases

Airnov enlarges portfolio with a new and innovative addition to meet evolving customers’ needs

HAT®-B, launched in July 2022, is the latest product in the HAT product line designed to protect test strips, pharmaceuticals, and nutraceuticals from moisture. Capacity increased in China to produce higher quantities of HAT-SNAP to answer soaring market demand in this region. Sustainability continues to be a key consideration for Airnov when designing new products.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement